| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 68 | 2021 | 1531 | 8.130 |
Why?
|
| Antihypertensive Agents | 47 | 2021 | 497 | 6.400 |
Why?
|
| Blood Pressure | 38 | 2021 | 1447 | 3.150 |
Why?
|
| Cardiovascular Diseases | 23 | 2016 | 938 | 2.900 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2021 | 1085 | 2.340 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 7 | 2020 | 87 | 1.640 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2010 | 189 | 1.430 |
Why?
|
| Practice Guidelines as Topic | 11 | 2020 | 772 | 1.390 |
Why?
|
| Hypoglycemic Agents | 4 | 2016 | 361 | 1.340 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 9 | 2010 | 201 | 1.220 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2013 | 161 | 1.130 |
Why?
|
| Angiotensin Receptor Antagonists | 5 | 2010 | 155 | 1.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2010 | 95 | 0.990 |
Why?
|
| Primary Health Care | 5 | 2015 | 702 | 0.960 |
Why?
|
| Hydrochlorothiazide | 3 | 2013 | 15 | 0.940 |
Why?
|
| Chlorthalidone | 6 | 2014 | 10 | 0.940 |
Why?
|
| Calcium Channel Blockers | 9 | 2010 | 137 | 0.920 |
Why?
|
| Kidney Diseases | 4 | 2010 | 307 | 0.920 |
Why?
|
| Diuretics | 5 | 2011 | 96 | 0.860 |
Why?
|
| Humans | 86 | 2021 | 68525 | 0.830 |
Why?
|
| Risk Factors | 23 | 2016 | 5719 | 0.800 |
Why?
|
| Potassium | 2 | 2013 | 168 | 0.770 |
Why?
|
| Drug Therapy, Combination | 12 | 2016 | 648 | 0.750 |
Why?
|
| Albuminuria | 2 | 2013 | 171 | 0.730 |
Why?
|
| Life Style | 8 | 2010 | 338 | 0.710 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2009 | 140 | 0.630 |
Why?
|
| Glomerular Filtration Rate | 6 | 2013 | 274 | 0.620 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2014 | 929 | 0.580 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2016 | 13 | 0.550 |
Why?
|
| Systole | 6 | 2016 | 149 | 0.530 |
Why?
|
| Congresses as Topic | 1 | 2015 | 85 | 0.520 |
Why?
|
| Hyperglycemia | 2 | 2016 | 158 | 0.500 |
Why?
|
| Hypolipidemic Agents | 4 | 2011 | 82 | 0.500 |
Why?
|
| Ramipril | 2 | 2014 | 10 | 0.490 |
Why?
|
| Benzoates | 2 | 2014 | 20 | 0.480 |
Why?
|
| Hypertension, Renal | 1 | 2013 | 29 | 0.470 |
Why?
|
| Diabetic Angiopathies | 2 | 2013 | 203 | 0.470 |
Why?
|
| Bendroflumethiazide | 1 | 2013 | 1 | 0.460 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2013 | 17 | 0.450 |
Why?
|
| Membrane Transport Modulators | 1 | 2013 | 23 | 0.450 |
Why?
|
| Renin-Angiotensin System | 2 | 2010 | 78 | 0.450 |
Why?
|
| Drug Chronotherapy | 1 | 2012 | 2 | 0.450 |
Why?
|
| Uric Acid | 1 | 2013 | 37 | 0.450 |
Why?
|
| Heart Failure | 4 | 2009 | 1179 | 0.450 |
Why?
|
| Benzimidazoles | 2 | 2014 | 128 | 0.440 |
Why?
|
| Vasodilator Agents | 2 | 2010 | 138 | 0.440 |
Why?
|
| Blood Glucose | 3 | 2016 | 631 | 0.440 |
Why?
|
| Clinical Trials as Topic | 8 | 2014 | 848 | 0.430 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 198 | 0.420 |
Why?
|
| Pressoreceptors | 1 | 2012 | 15 | 0.420 |
Why?
|
| Mandatory Testing | 1 | 2011 | 3 | 0.420 |
Why?
|
| Societies, Medical | 3 | 2015 | 403 | 0.410 |
Why?
|
| Baroreflex | 1 | 2012 | 20 | 0.410 |
Why?
|
| Stroke | 5 | 2016 | 2161 | 0.400 |
Why?
|
| Fumarates | 1 | 2011 | 28 | 0.390 |
Why?
|
| Thiazepines | 1 | 2010 | 14 | 0.380 |
Why?
|
| Diabetes Complications | 4 | 2007 | 249 | 0.380 |
Why?
|
| Amides | 1 | 2011 | 86 | 0.370 |
Why?
|
| Neprilysin | 1 | 2010 | 55 | 0.370 |
Why?
|
| Proteinuria | 1 | 2010 | 136 | 0.360 |
Why?
|
| United States | 14 | 2020 | 7335 | 0.360 |
Why?
|
| Risk Assessment | 8 | 2016 | 2004 | 0.360 |
Why?
|
| Patient Compliance | 5 | 2013 | 402 | 0.340 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2009 | 45 | 0.340 |
Why?
|
| Myocardial Infarction | 5 | 2016 | 807 | 0.330 |
Why?
|
| Pyridines | 1 | 2010 | 261 | 0.330 |
Why?
|
| Treatment Outcome | 15 | 2016 | 7028 | 0.320 |
Why?
|
| Aged | 21 | 2021 | 14842 | 0.310 |
Why?
|
| Amlodipine | 7 | 2014 | 31 | 0.310 |
Why?
|
| Metabolic Syndrome | 2 | 2008 | 191 | 0.300 |
Why?
|
| Anemia | 1 | 2007 | 104 | 0.290 |
Why?
|
| Diabetes Mellitus | 4 | 2008 | 693 | 0.280 |
Why?
|
| Dietary Supplements | 1 | 2009 | 331 | 0.280 |
Why?
|
| Benzopyrans | 3 | 2010 | 21 | 0.260 |
Why?
|
| Ethanolamines | 3 | 2010 | 33 | 0.260 |
Why?
|
| Diet | 2 | 2010 | 513 | 0.260 |
Why?
|
| Pravastatin | 3 | 2013 | 4 | 0.250 |
Why?
|
| Male | 28 | 2020 | 37281 | 0.240 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 158 | 0.240 |
Why?
|
| Obesity | 2 | 2009 | 1074 | 0.240 |
Why?
|
| Database Management Systems | 1 | 2004 | 25 | 0.240 |
Why?
|
| Public Health Practice | 1 | 2003 | 23 | 0.240 |
Why?
|
| Female | 27 | 2016 | 38015 | 0.230 |
Why?
|
| Population Surveillance | 2 | 2011 | 285 | 0.230 |
Why?
|
| Prevalence | 6 | 2020 | 1609 | 0.230 |
Why?
|
| Middle Aged | 21 | 2016 | 21119 | 0.230 |
Why?
|
| Double-Blind Method | 9 | 2016 | 1737 | 0.220 |
Why?
|
| Sodium-Glucose Transporter 2 | 2 | 2013 | 3 | 0.220 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2003 | 141 | 0.220 |
Why?
|
| Hyperlipidemias | 2 | 2013 | 90 | 0.220 |
Why?
|
| Disease Progression | 5 | 2011 | 1037 | 0.210 |
Why?
|
| United Kingdom | 2 | 2011 | 152 | 0.200 |
Why?
|
| Cardiovascular Agents | 1 | 2002 | 82 | 0.200 |
Why?
|
| China | 1 | 2021 | 138 | 0.200 |
Why?
|
| Nebivolol | 3 | 2010 | 6 | 0.190 |
Why?
|
| Treatment Failure | 2 | 2012 | 216 | 0.190 |
Why?
|
| Aspirin | 1 | 2001 | 295 | 0.180 |
Why?
|
| Evidence-Based Medicine | 3 | 2011 | 438 | 0.170 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2001 | 277 | 0.170 |
Why?
|
| Neoplasms | 1 | 2010 | 1660 | 0.170 |
Why?
|
| Coronary Disease | 3 | 2013 | 358 | 0.160 |
Why?
|
| Lisinopril | 5 | 2014 | 16 | 0.160 |
Why?
|
| Kidney | 2 | 2014 | 945 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2021 | 3702 | 0.150 |
Why?
|
| Comorbidity | 3 | 2016 | 1425 | 0.150 |
Why?
|
| Prognosis | 4 | 2016 | 2093 | 0.150 |
Why?
|
| Hypotension, Orthostatic | 1 | 2016 | 15 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 3256 | 0.140 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2016 | 20 | 0.140 |
Why?
|
| Drug Interactions | 2 | 2010 | 289 | 0.140 |
Why?
|
| Drug Combinations | 2 | 2010 | 304 | 0.130 |
Why?
|
| Lupus Nephritis | 1 | 2017 | 193 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 503 | 0.130 |
Why?
|
| Hypercholesterolemia | 2 | 2008 | 86 | 0.130 |
Why?
|
| Inpatients | 1 | 2016 | 208 | 0.120 |
Why?
|
| Sympathectomy | 1 | 2014 | 24 | 0.120 |
Why?
|
| Blood Pressure Determination | 4 | 2016 | 149 | 0.120 |
Why?
|
| Dihydroxycholecalciferols | 1 | 1993 | 19 | 0.120 |
Why?
|
| Peripheral Arterial Disease | 1 | 2014 | 83 | 0.120 |
Why?
|
| Calcium, Dietary | 1 | 1993 | 35 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2013 | 18 | 0.110 |
Why?
|
| Sarcoidosis | 1 | 1993 | 77 | 0.110 |
Why?
|
| Renin | 2 | 2010 | 96 | 0.110 |
Why?
|
| Adult | 9 | 2017 | 21375 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2010 | 1329 | 0.110 |
Why?
|
| Cardiovascular System | 1 | 2012 | 85 | 0.100 |
Why?
|
| Coronary Artery Disease | 2 | 2009 | 696 | 0.100 |
Why?
|
| Lipids | 1 | 2013 | 298 | 0.100 |
Why?
|
| Gluconeogenesis | 1 | 2011 | 7 | 0.100 |
Why?
|
| Canagliflozin | 1 | 2011 | 3 | 0.100 |
Why?
|
| Glucosides | 1 | 2011 | 16 | 0.100 |
Why?
|
| Survival Rate | 4 | 2016 | 1055 | 0.100 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2010 | 8 | 0.100 |
Why?
|
| Benzhydryl Compounds | 1 | 2011 | 62 | 0.100 |
Why?
|
| Thiophenes | 1 | 2011 | 76 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 186 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 57 | 0.100 |
Why?
|
| Early Diagnosis | 2 | 2009 | 122 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2011 | 117 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2017 | 756 | 0.090 |
Why?
|
| Doxazosin | 3 | 2008 | 20 | 0.090 |
Why?
|
| Valsartan | 1 | 2010 | 99 | 0.090 |
Why?
|
| Acute Coronary Syndrome | 1 | 2011 | 195 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 122 | 0.090 |
Why?
|
| Aminobutyrates | 1 | 2010 | 94 | 0.090 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 14 | 0.090 |
Why?
|
| Homeostasis | 1 | 2011 | 291 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2010 | 184 | 0.090 |
Why?
|
| Tetrazoles | 1 | 2010 | 160 | 0.090 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 136 | 0.090 |
Why?
|
| Glycerophospholipids | 1 | 2009 | 20 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2010 | 223 | 0.090 |
Why?
|
| Sodium | 1 | 2009 | 161 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 186 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 503 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1039 | 0.080 |
Why?
|
| Benzazepines | 1 | 2009 | 104 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 371 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 49 | 0.080 |
Why?
|
| Nitric Oxide | 1 | 2010 | 382 | 0.080 |
Why?
|
| Erythropoiesis | 1 | 2007 | 24 | 0.080 |
Why?
|
| Ferritins | 1 | 2007 | 49 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 239 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 4843 | 0.080 |
Why?
|
| Erythropoietin | 1 | 2007 | 96 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 866 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2009 | 193 | 0.070 |
Why?
|
| Patient Selection | 3 | 2010 | 592 | 0.070 |
Why?
|
| History, 19th Century | 1 | 2006 | 95 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 581 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2006 | 126 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1465 | 0.070 |
Why?
|
| Incidence | 4 | 2016 | 1582 | 0.070 |
Why?
|
| Pain | 1 | 2010 | 472 | 0.070 |
Why?
|
| Diabetic Nephropathies | 1 | 2007 | 161 | 0.070 |
Why?
|
| Community Networks | 1 | 2006 | 96 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2006 | 248 | 0.070 |
Why?
|
| Age Factors | 1 | 2011 | 1860 | 0.070 |
Why?
|
| Southeastern United States | 1 | 2006 | 281 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2013 | 212 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 742 | 0.070 |
Why?
|
| Sympathetic Nervous System | 1 | 2005 | 81 | 0.070 |
Why?
|
| Algorithms | 2 | 2009 | 1194 | 0.070 |
Why?
|
| Cardiotonic Agents | 1 | 2005 | 71 | 0.070 |
Why?
|
| Nitrendipine | 1 | 2004 | 8 | 0.060 |
Why?
|
| Verapamil | 1 | 2004 | 30 | 0.060 |
Why?
|
| Nifedipine | 1 | 2004 | 40 | 0.060 |
Why?
|
| Dyslipidemias | 1 | 2006 | 98 | 0.060 |
Why?
|
| Risk | 2 | 2006 | 563 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 172 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2005 | 135 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2007 | 718 | 0.060 |
Why?
|
| Medical Records | 1 | 2004 | 121 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2004 | 161 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1745 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 805 | 0.060 |
Why?
|
| Health Promotion | 1 | 2006 | 407 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 1851 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2002 | 47 | 0.050 |
Why?
|
| Digoxin | 1 | 2002 | 24 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2004 | 714 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2016 | 272 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2005 | 310 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2004 | 284 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 791 | 0.050 |
Why?
|
| Cholesterol, Dietary | 1 | 2001 | 22 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 951 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 536 | 0.050 |
Why?
|
| South Carolina | 2 | 2006 | 2750 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 2798 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 424 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 18 | 0.050 |
Why?
|
| American Medical Association | 1 | 2020 | 21 | 0.050 |
Why?
|
| Hypokalemia | 2 | 2010 | 12 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2001 | 224 | 0.040 |
Why?
|
| Drug Costs | 1 | 2000 | 87 | 0.040 |
Why?
|
| American Heart Association | 1 | 2020 | 142 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2001 | 373 | 0.040 |
Why?
|
| Quality of Life | 1 | 2007 | 1515 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 567 | 0.040 |
Why?
|
| Health Policy | 1 | 2020 | 221 | 0.040 |
Why?
|
| Exercise | 1 | 2004 | 657 | 0.040 |
Why?
|
| Alcoholism | 1 | 2005 | 1109 | 0.040 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2010 | 32 | 0.040 |
Why?
|
| Canada | 1 | 2016 | 266 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 319 | 0.030 |
Why?
|
| Basal Metabolism | 1 | 1995 | 22 | 0.030 |
Why?
|
| Animals | 1 | 2013 | 20877 | 0.030 |
Why?
|
| Menstrual Cycle | 1 | 1995 | 64 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2005 | 2356 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1993 | 38 | 0.030 |
Why?
|
| Logistic Models | 2 | 2008 | 1419 | 0.030 |
Why?
|
| Research Design | 2 | 2007 | 729 | 0.030 |
Why?
|
| Biopsy | 1 | 1993 | 539 | 0.020 |
Why?
|
| Mortality | 1 | 2011 | 162 | 0.020 |
Why?
|
| Skin | 1 | 1993 | 451 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 243 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 420 | 0.020 |
Why?
|
| Calcium | 1 | 1993 | 929 | 0.020 |
Why?
|
| Time Factors | 2 | 2013 | 4655 | 0.020 |
Why?
|
| Vitamin D | 1 | 1993 | 516 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2011 | 326 | 0.020 |
Why?
|
| Cholesterol | 1 | 2008 | 331 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1548 | 0.020 |
Why?
|
| Georgia | 1 | 2006 | 161 | 0.020 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 52 | 0.020 |
Why?
|
| North Carolina | 1 | 2006 | 224 | 0.020 |
Why?
|
| Angioedema | 1 | 2006 | 41 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2010 | 335 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2005 | 80 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2010 | 657 | 0.020 |
Why?
|
| Sample Size | 1 | 2005 | 79 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 112 | 0.020 |
Why?
|
| Reminder Systems | 1 | 2005 | 39 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 188 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 365 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2005 | 82 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 766 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2006 | 185 | 0.020 |
Why?
|
| Central Nervous System Depressants | 1 | 2005 | 182 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 329 | 0.010 |
Why?
|
| Heart Rate | 1 | 2005 | 568 | 0.010 |
Why?
|
| Health Education | 1 | 2005 | 279 | 0.010 |
Why?
|
| Ethanol | 1 | 2005 | 892 | 0.010 |
Why?
|